39506-61-1

Basic information

• Product Name: 5-Methylsalicylamide
• Synonyms: 5-METHYL SALICYLAMIDE;5-METHYLSALICYAMIDE;Benzamide, 2-hydroxy-5-methyl- (9CI);8023 5-METHYL SALICYLAMIDE;5-Methyl salicylamide ,98%;2-HYDROXY-5-METHYLBENZAMIDE
• CAS NO: 39506-61-1
• Molecular Formula: C₈H₉NO₂
• Molecular Weight: 151.16
• Product Categories: AMIDE;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 39506-61-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 182 °C
• Boiling Point: 278.886 °C at 760 mmHg
• Flash Point: 122.466 °C
• Appearance: /
• Density: 1.231 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 5-Methylsalicylamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methylsalicylamide(39506-61-1)
• EPA Substance Registry System: 5-Methylsalicylamide(39506-61-1)

Safety Data

• Hazardous Substances Data: 39506-61-1(Hazardous Substances Data)

Usage

General Description

5-Methylsalicylamide is a chemical compound that is derived from salicylic acid and has a methyl group attached to the aromatic ring. It is primarily used as an intermediate in the synthesis of other organic compounds and pharmaceutical drugs. 5-Methylsalicylamide has anti-inflammatory and analgesic properties, which make it a potential candidate for the development of new pain-relief medications. It is also used as a stabilizer in the production of certain polymers and plastics. However, 5-Methylsalicylamide should be handled and used with care, as it may cause irritation to the skin, eyes, and respiratory system, and should only be used in accordance with proper safety protocols.

InChI:InChI=1/C8H9NO2/c1-5-2-3-7(10)6(4-5)8(9)11/h2-4,10H,1H3,(H2,9,11)

Upstream product

• 1450-72-2 5-methyl-2-hydroxyacetophenone 
• 58138-59-3 2-acetoxy-5-methylbenzoyl chloride 
• 22717-57-3 methyl 6-hydroxy-m-toluate 
• 34265-58-2 ethyl 5-methylsalicylate 
• 24088-76-4 6-methyl-benzo[e][1,3]oxazine-2,4-dione 

Downstream Products

• 58952-00-4 4-hydroxytoluene-3-thiocarboxylic acid amide 
• 1056954-31-4 2-carbamoyl-4-methylphenyl acetate 
• 165679-42-5 2-(2-Fluoro-phenyl)-6-methyl-benzo[e][1,3]oxazin-4-one 

Relevant articles and documents

Asymmetric Hydrogenation of Cationic Intermediates for the Synthesis of Chiral N,O-Acetals

For over half a century, transition-metal-catalyzed homogeneous hydrogenation has been mainly focused on neutral and readily prepared unsaturated substrates. Although the addition of molecular hydrogen to C=C, C=N, and C=O bonds represents a well-studied paradigm, the asymmetric hydrogenation of cationic species remains an underdeveloped area. In this study, we were seeking a breakthrough in asymmetric hydrogenation, with cationic intermediates as targets, and thereby anticipating applying this powerful tool to the construction of challenging chiral molecules. Under acidic conditions, both N- or O-acetylsalicylamides underwent cyclization to generate cationic intermediates, which were subsequently reduced by an iridium or rhodium hydride complex. The resulting N,O-acetals were synthesized with remarkably high enantioselectivity. This catalytic strategy exhibited high efficiency (turnover number of up to 4400) and high chemoselectivity. Mechanistic studies supported the hypothesis that a cationic intermediate was formed in situ and hydrogenated afterwards. A catalytic cycle has been proposed with hydride transfer from the iridium complex to the cationic sp2 carbon atom being the rate-determining step. A steric map of the catalyst has been created to illustrate the chiral environment, and a quantitative structure–selectivity relationship analysis showed how enantiomeric induction was achieved in this chemical transformation.

Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof

The present invention provides compounds of formula I: along with methods of use of these compounds as pharmaceuticals, particularly in the treatment of obesity, metabolic syndrome, atherosclerosis, cardiovascular disease, insulin resistance, diseases ass